Completed PHASE3 INTERVENTIONAL 2-arm NCT00551642

Safety and Efficacy Study of Nitric Oxide for Inhalation on Chronic Lung Disease in Premature Babies

The Effects of Nitric Oxide for Inhalation on the Development of Chronic Lung Disease in Pre-term Infants

Sponsor: Mallinckrodt

Updated 7 times since 2017 Last updated: Feb 4, 2021 Started: May 29, 2005 Primary completion: Mar 16, 2008 Completion: Jul 17, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00551642, this PHASE3 trial focuses on Lung Disease and remains completed. Sponsored by Mallinckrodt, it has been updated 7 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Mar 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Mar 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

May 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mallinckrodt

Data source: Mallinckrodt

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ancona, Italy , Barakaldo, Spain , Barcelona, Spain , Bergamo, Italy , Berlin, Germany , Bologna, Italy , Brussels, Belgium , Charleroi, Belgium , Créteil, France , Edegem, Belgium and 24 more locations